2016-11-03T11:31:44-05:00 2015-12-31 221430039 SOBEL AND CO LLC CPA'S 293 EISENHOWER PARKWAY LIVINGSTON NJ 070391711 990 2015-01-01 208735688 SOLVING KIDS CANCER INC SOLV 2125886624 1 EAST 53RD STREET 5TH FLOOR NEW YORK NY 10022 SCOTT KENNEDY EXECUTIVE DIRECTOR 2125886624 2016-11-03 1 BRIDGET HARTNETT P01429163 9739949494 2016-11-03 2015 2017-02-10 21:41:12Z SCOTT KENNEDY 1 EAST 53RD STREET 5TH FLOOR NEW YORK NY 10022 938494 0 X WWW.SOLVINGKIDSCANCER.ORG X 2006 NY SOLVING KIDS' CANCER IMPROVES SURVIVAL OUTCOMES FOR THE DEADLIEST CHILDHOOD CANCERS BY CONTINUOUSLY INFLUENCING, ACCELERATING AND SUPPORTING NOVEL CLINICAL RESEARCH THAT DIRECTLY IMPACTS CHILDREN AS MORE EFFECTIVE AND LESS TOXIC TREATMENTS. 100% OF NON-BOARD (PUBLIC) DONATIONS ARE USED FOR FUNDING OUR MISSION PROGRAMS THROUGH GRANTS. 7 6 6 16 0 0 1381381 761768 0 0 5638 5202 -135453 -31332 1251566 735638 477288 395420 0 0 468256 570204 0 0 213774 262522 338552 1208066 1304176 43500 -568538 3170173 2567323 89730 55418 3080443 2511905 X SOLVING KIDS' CANCER IMPROVES SURVIVAL OUTCOMES FOR THE DEADLIEST CHILDHOOD CANCERS BY CONTINUOUSLY INFLUENCING, ACCELERATING AND SUPPORTING NOVEL CLINICAL RESEARCH THAT DIRECTLY IMPACTS CHILDREN AS MORE EFFECTIVE AND LESS TOXIC TREATMENTS. 100% OF NON-BOARD (PUBLIC) DONATIONS ARE USED FOR FUNDING OUR MISSION PROGRAMS THROUGH GRANTS. 0 0 767265 395420 SKC ACTIVELY PURSUES THE UNDERSTANDING OF THE RESEARCH LANDSCAPE FOR NEUROBLASTOMA, HIGH-RISK BRAIN TUMORS AND SARCOMAS AND DEVELOPS CLINICAL RESEARCH PROGRAMS TO ADDRESS THE CURRENT UNMET NEEDS OF CHILDREN CURRENTLY AFFECTED BY THESE DISEASES AND CHILDREN YET TO BE DIAGNOSED. SURVIVAL RATES REMAIN UNSATISFACTORILY LOW FOR THE DEADLIEST CHILDHOOD CANCERS AND SKC PRIORITIZES THE DELIVERY OF TRANSFORMATIVE, NEXT-GENERATION CANCER THERAPIES TO THIS POPULATION THAT INCLUDES IMMUNOTHERAPY, VACCINES, CELLULAR THERAPY, NOVEL/SYNERGISTIC COMBINATION TREATMENTS, NEW TARGETED DRUGS, INTERVENTIONAL RADIOLOGY TECHNIQUES AND NOVEL THERAPY DELIVERY MECHANISMS. OUR CRITERIA FOR IDENTIFYING AND SUPPORTING THESE NOVEL APPROACHES AIMS TO PROVIDE MORE EFFECTIVE AND LESS TREATMENT OPTIONS THAN THE CURRENT STANDARD-OF-CARE. SKC HAS HELPED TO DEVELOP 23 CLINICAL TRIALS FOR CHILDREN RESULTING IN 22 NEW EXPERIMENTAL TREATMENT OPTIONS FOR CHILDREN WITH HIGH-RISK CANCERS. IN 2015, SKC HELPED PRIORITIZE, DEVELOP AND GRANT SUPPORT FOR SEVERAL IMPORTANT MISSION PROGRAMS INCLUDING: A PH I CLINICAL TRIAL USING GENETICALLY ENGINEERED CAR T-CELLS TARGETING GD2 IN NEUROBLASTOMA; MODIFYING THE PH I TRIAL TO INCLUDE AN ANTI-PD1 CHECKPOINT INHIBITOR IN COMBINATION WITH THE CAR T-CELLS; A PH I CLINICAL TRIAL INVESTIGATING THE COMBINATION OF AN ANTI-PD1 CHECKPOINT INHIBITOR AND AN ANTI-CTLA4 CHECKPOINT INHIBITOR IN CHILDREN WITH HIGH-GRADE BRAIN TUMORS; A PH I CLINICAL TRIAL USING T-CELLS MODIFIED WITH BISPECIFIC THERAPEUTIC ANTIBODIES FOR CHILDREN WITH SARCOMAS AND NEUROBLASTOMA; A PH I CLINICAL TRIAL USING A PATIENT'S OWN T-CELLS MODIFIED WITH 4 TUMOR ANTIGENS FOR CHILDREN WITH NEUROBLASTOMA AND SARCOMAS; A PH I CLINICAL TRIAL USING A TRIPLE COMBINATION OF ANTI-GD2 THERAPEUTIC ANTIBODIES + SYSTEMIC RADIOTHERAPY USING MIBG + ANTI-PD1 CHECKPOINT INHIBITORS IN A TRANSATLANTIC CLINICAL TRIAL IN 3 COUNTRIES. 767265 1 1 0 0 0 0 0 0 0 0 1 0 0 0 0 1 1 0 0 0 0 1 0 1 1 0 0 1 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 12 0 1 6 1 0 0 0 0 0 1 1 0 0 0 0 X 7 6 1 0 0 0 0 0 0 1 1 0 0 1 1 1 1 1 1 1 1 0 NY X THE ORGANIZATION 2125886624 1 EAST 53RD STREET 5TH FLOOR NEW YORK NY 10022 JOHN LONDON CHAIRMAN, CO-FOUNDER 2.00 X X 0 0 0 SCOTT KENNEDY EXECUTIVE DIRECTOR, CO-FOU 40.00 X X 156250 0 27383 KHALIL BARRAGE DIRECTOR 2.00 X 0 0 0 CATHERINE LONDON DIRECTOR 2.00 X 0 0 0 ARI SPAR DIRECTOR 2.00 X 0 0 0 CHANNING STAVE SECRETARY 2.00 X X 0 0 0 MARK SAVOYE DIRECTOR 2.00 X 0 0 0 156250 0 27383 1 0 1 0 0 427258 334510 761768 5202 5202 171524 427258 202856 -31332 -31332 735638 0 0 -26130 X 320420 320420 75000 75000 183633 166792 4159 12682 320576 97938 72795 149843 38032 14640 5777 17615 27963 11015 6969 9979 16323 16323 134633 69345 53288 12000 6253 6253 6762 6762 96494 11366 85128 5802 426 3855 1521 39725 39725 1917 1917 MISCELLANEOUS 14125 323 11142 2660 PRINTING AND SHIPPING 10167 3168 6999 MEALS AND ENTERTAINMENT 2975 2500 475 DATABASE EXPENSE 2214 2214 1162 1162 1304176 767265 323137 213774 204268 99538 2815988 2300960 5000 77000 67505 18843 214969 150422 73827 64547 3585 6435 3170173 2567323 39730 55418 50000 0 89730 55418 X 2630631 2078455 449812 433450 3080443 2511905 3170173 2567323 -568538 0 X X 0 1 X 1 0 X 1047437 738702 309184 1381381 761768 4238472 1047437 738702 309184 1381381 761768 4238472 440060 3798412 15625 11123 7027 5638 5202 44615 4283087 0.88680 0.88510 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 5160 4461 699 209809 145961 63848 64547 X 735638 0 735638 0 735638 1304176 0 1304176 0 1304176 PART X, LINE 2: THE ORGANIZATION FOLLOWS STANDARDS THAT PROVIDE CLARIFICATION ON ACCOUNTING FOR UNCERTAINTY IN INCOME TAXES RECOGNIZED IN THE ORGANIZATION'S FINANCIAL STATEMENTS. THE GUIDANCE PRESCRIBES A RECOGNITION THRESHOLD AND MEASUREMENT ATTRIBUTE FOR THE RECOGNITION AND MEASUREMENT OF A TAX POSITION TAKEN OR EXPECTED TO BE TAKEN IN A TAX RETURN, AND ALSO PROVIDES GUIDANCE ON DERECOGNITION, CLASSIFICATION, INTEREST AND PENALTIES, DISCLOSURE AND TRANSITION. THE ORGANIZATION'S POLICY IS TO RECOGNIZE INTEREST AND PENALTIES ON UNRECOGNIZED TAX BENEFITS IN INCOME TAX EXPENSE. NO INTEREST AND PENALTIES WERE RECORDED DURING 2015 AND 2014. THE TAX YEARS SUBJECT TO AUDIT BY FEDERAL AND STATE JURISDICTIONS ARE THE YEARS ENDED DECEMBER 31, 2012 AND FORWARD. AT DECEMBER 31, 2015 AND 2014, THERE ARE NO SIGNIFICANT INCOME TAX UNCERTAINTIES. 0 0 0 0 0 0 0 0 0 0 UNITED KINDGOM CANCER RESEARCH 75000 CHECK FMV 1 0 0 0 0 0 0 X X X X 0 ASTIC PRODUCTIONS 850 SEVENTH AVENUE NEW YORK NY 10019 ORGANIZATION OF SPRING CELEBRATION 0 598702 52500 546202 598702 52500 546202 SPRING CELEBRATION 598702 427258 171444 83376 12422 99952 JUNIOR BOARD EVENT 80 80 7106 598782 427258 171524 83376 12422 107058 202856 -31332 SCHEDULE G, PART I, LINE 2B, COLUMN (V) PAYMENTS WERE MADE TO FUNDRAISER TO HELP ORGANIZE THE SPRING CELEBRATION 1 BAYLOR COLLEGE OF MEDICINE ONE BAYLOR PLAZA HOUSTON TX 77030 741613878 501(C)(3) 226496 CASH CANCER RESEARCH JOHNS HOPKINS UNIVERSITY 242 GARLAND HALL BALTIMORE MD 21218 520595110 501(C)(3) 73924 CASH CANCER RESEARCH MEMORIAL SLOAN KETTERING CANCER CENTER 633 THIRD AVENUE 28TH FLOOR NEW YORK NY 10017 131924236 501(C)(3) 20000 CASH CANCER RESEARCH 3 PART I, LINE 2: THE ORGANIZATION EXPENDS FUNDS IN CONNECTION WITH GRANT COMMITMENTS AS EACH GRANTEE ACCOMPLISHES SPECIFIC MILESTONES SET FORTH IN EACH GRANT AGREEMENT. EACH GRANTEE IS REQUIRED TO SUBMIT PROGRESS REPORTS ON A PERIODIC BASIS AS MILESTONES ARE ACHIEVED PURSUANT TO THE GRANT AGREEMENTS. X X X 0 0 0 0 0 0 0 0 0 SCOTT KENNEDY EXECUTIVE DIRECTOR, CO-FOU 156250 0 0 0 0 0 0 0 27383 0 183633 0 0 0 PART I, LINE 3 FAIR MARKET VALUE COMPARISON OF SIMILAR ORGANIZATIONS FORM 990, PART VI, SECTION A, LINE 2 JOHN LONDON AND CATHERINE LONDON ARE MARRIED. FORM 990, PART VI, SECTION B, LINE 11 THE COMPLETED FORM 990 IS SENT TO THE BOARD OF DIRECTORS PRIOR TO FILING FOR REVIEW AND APPROVAL. FORM 990, PART VI, SECTION B, LINE 12C THE ORGANIZATION DISTRIBUTES A CONFLICT OF INTEREST POLICY TO EACH BOARD MEMBER ANNUALLY AT THE BOARD MEETING. ALL STAFF AND BOARD MEMBERS ARE REQUIRED TO SIGN A CONFLICT OF INTEREST POLICY STATEMENT ON AN ANNUAL BASIS. ANY CONFLICTS THAT ARISE DURING THE COURSE OF THE YEAR ARE REQUIRED TO BE DISCLOSED AND RESOLVED BEFORE THE TRANSACTION IS COMPLETED. FORM 990, PART VI, SECTION B, LINE 15 COMPENSATION IS DETERMINED BY CONDUCTING A FAIR MARET VALUE COMPARISON OF OTHER ORGANIZATIONS BY THE BOARD CHAIR. FACTORS INCLUDE THE NUMBER OF HOURS WORKED AND THE BREADTH OF ROLES AND RESPONSIBILITIES. FORM 990, PART VI, SECTION C, LINE 18 THE ORGANIZATION'S FORM 990 IS AVAILABLE UPON REQUEST. FORM 990, PART VI, SECTION C, LINE 19 THE ORGANIZATION'S GOVERNING DOCUMENTS IS MADE AVAILABLE UPON REQUEST. FORM 990, PART IX, LINE 11G BANK AND CREDIT CARD FEES: PROGRAM SERVICE EXPENSES 0. MANAGEMENT AND GENERAL EXPENSES 2,759. FUNDRAISING EXPENSES 0. TOTAL EXPENSES 2,759. MERCHANT FEES: PROGRAM SERVICE EXPENSES 0. MANAGEMENT AND GENERAL EXPENSES 10,917. FUNDRAISING EXPENSES 0. TOTAL EXPENSES 10,917. SCIENTIFIC CONSULTING: PROGRAM SERVICE EXPENSES 69,345. MANAGEMENT AND GENERAL EXPENSES 0. FUNDRAISING EXPENSES 0. TOTAL EXPENSES 69,345. PUBLIC RELATIONS: PROGRAM SERVICE EXPENSES 0. MANAGEMENT AND GENERAL EXPENSES 12,000. FUNDRAISING EXPENSES 12,000. TOTAL EXPENSES 24,000. PROGAMMATIC CONSULTANT: PROGRAM SERVICE EXPENSES 0. MANAGEMENT AND GENERAL EXPENSES 27,612. FUNDRAISING EXPENSES 0. TOTAL EXPENSES 27,612. FORM 990, PART XII, LINE 2C THE BOARD OF DIRECTORS IS CHARGED WITH OVERSIGHT IN REGARDS TO REVIEW OF THE FINANCIALS AND SELECTION OF THE AUDITOR.